Aurobindo Pharma Ltd. — Regulatory Filings 2020

Apr 21, 2020

21[st] April 2020

ToListing Department,NATIONAL STOCK EXCHANGE OF INDIA LIMITEDExchange Plaza,Bandra Kurla Complex, Bandra (E),MUMBAI -400 051Company Code No. AUROPHARMA	ToThe Corporate Relations DepartmentBSE LIMITEDPhiroz Jeejeebhoy Towers,25thfloor, Dalal Street,MUMBAI -400 001Company Code No. 524804

Dear Sirs,

Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Update on Unit IV inspection conducted between Nov 4[th] -13[th] , 2019

Dear Sir/Mam,

Further to our intimations dated 13[th] November 2019, 19[th] February and 21[st] February 2020 with regard to the inspection of Unit IV, an injectable manufacturing formulation facility of the Company, conducted between Nov 4th-13th, 2019, we would like to inform that US FDA has determined that the inspection classification of this facility is Voluntary Action Indicated (VAI).

Please take the above information on record.

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

==> picture [74 x 18] intentionally omitted <==

B.Adi Reddy Company Secretary